DXR vs. DRIO, LUCD, NSPR, XAIR, CTSO, APYX, CTCX, ICCM, CODX, and LNSR
Should you be buying Daxor stock or one of its competitors? The main competitors of Daxor include DarioHealth (DRIO), Lucid Diagnostics (LUCD), InspireMD (NSPR), Beyond Air (XAIR), Cytosorbents (CTSO), Apyx Medical (APYX), Carmell (CTCX), IceCure Medical (ICCM), Co-Diagnostics (CODX), and LENSAR (LNSR). These companies are all part of the "surgical & medical instruments" industry.
DarioHealth (NASDAQ:DRIO) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership, community ranking and earnings.
DarioHealth has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500. Comparatively, Daxor has a beta of -0.45, suggesting that its stock price is 145% less volatile than the S&P 500.
In the previous week, DarioHealth and DarioHealth both had 3 articles in the media. DarioHealth's average media sentiment score of 1.18 beat Daxor's score of 0.93 indicating that Daxor is being referred to more favorably in the news media.
Daxor has lower revenue, but higher earnings than DarioHealth.
Daxor has a net margin of 0.00% compared to Daxor's net margin of -165.96%. DarioHealth's return on equity of 0.00% beat Daxor's return on equity.
DarioHealth presently has a consensus target price of $4.05, suggesting a potential upside of 157.96%. Given Daxor's higher probable upside, equities analysts plainly believe DarioHealth is more favorable than Daxor.
33.4% of DarioHealth shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 15.7% of DarioHealth shares are held by insiders. Comparatively, 60.6% of Daxor shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
DarioHealth received 238 more outperform votes than Daxor when rated by MarketBeat users.
Summary
DarioHealth beats Daxor on 6 of the 11 factors compared between the two stocks.
Get Daxor News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
